Immunoassay Market Surpass US$ 37,987.76 million by 2027 Says, The Insight Partners

According to our new research study on "Immunoassay Market Forecast to 2027 - Global Analysis - by Product, Technology, Application, End User, and Geography," the market size is expected to reach US$ 37,987.76 million by 2027 from US$ 21,800.00 million in 2018; it is estimated to grow at a CAGR of 6.5% during 2019-2027.

Immunoassays (IAs) are bioanalytical technique in which the quantitation of analytes relies on the reaction of an antigen and an antibody. Immunoassays play a vital role in many bioanalytical settings, such as biopharmaceutical analysis, clinical diagnostics, security, environmental monitoring, and food testing. The significance and efficacy of immunoassay methods in the pharmaceutical research are credited to their inherent high throughput, specificity, and high sensitivity for the analysis of various analytes in biological samples.

Request for sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00005380/?utm_source=OpenPR&utm_medium=10144

Immunoassay Market: Competitive Landscape and Key Developments

Siemens; BD; bioMérieux SA; Abbott; F. Hoffmann La-Roche Ltd.; Danaher; Ortho Clinical Diagnostics (Johnson & Johnson Services, Inc.); Sysmex Corporation; Thermo Fisher Scientific, Inc.; and Quidel Corporation are among the leading companies in the immunoassay market. The immunoassay market share is anticipated to flourish with the development of new innovative products by market players.

In January 2019, F. Hoffmann La-Roche Ltd launched cobas pro integrated solutions, which are now available for countries accepting the CE mark. This next generation of innovation in the Serum Work Area marks a significant milestone in evolving laboratory diagnostic workflow and continues with Roche's long tradition as a leader in lab consolidation.
In April 2019, F. Hoffmann La-Roche Ltd launched new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients.

In May 2018, Abbott announced the launch of its Afinion 2 analyzer in the US, the newest generation of the Afinion test system.

In February 2018, Siemens Healthineers announced that it received 510(k) clearance from the US. Food and Drug Administration for its Blood Urea Nitrogen (BUN) and Total Carbon Dioxide (TCO2) point-of-care tests aid in diagnosing renal diseases and metabolic imbalances.

The global immunoassay market, based on application, is segmented into therapeutic drug monitoring, oncology, cardiology, endocrinology, infectious disease testing, autoimmune diseases, and others. The therapeutic drug monitoring segment was the largest among application subsegments in the immunoassay market in 2018. However, the infectious disease testing segment is expected to witness growth in its demand at the fastest CAGR of 7.0% during 2019 to 2027.

In recent years, the biotechnology industry is developing at an extraordinarily rapid speed. Manufacturers are confronting various healthcare difficulties through the latest medicines, progressing digitalization, therapy forms, and continuously changing the management. As per the statistics from the World Health Organization (WHO), the population around the globe is rising by 1.2% per annum, leading to growth in population in the elderly class. The WHO also reveals that the balance of people aged 65-80 will increase to 28% in 2030, as compared to 22% in 2000. The Government of India, along with prime departments in India such as the Indian Council of Medical Research (ICMR), Department of Biotechnology (DBT), Council of Scientific and Industrial Research (CSIR), Indian Council of Agricultural Research (ICAR), Department of Science and Technology and others, is contributing significantly toward the growth of biotechnology application-based products and services in the country. The Government of India reported revenue of US$ 11.6 billion in 2017 for biotechnology. These factors are expected to increase biotechnology & biopharmaceutical industries to achieve efficient tests, which are predicted to drive the growth of the market

North America is largest market for immunoassay with the US holding the largest market share. The growth of the North American immunoassay market is characterized by the growing prevalence of various diseases, government support for medical devices adoption, and increasing efforts in R&D activities and other activities undertaken by the market players operating in the market. In addition, technological advancements in the diagnosis industry is likely to be a major growth stimulator for the immunoassay market in North America.

Place an Order copy of immunoassay market @ https://www.theinsightpartners.com/buy/TIPRE00005380/?utm_source=OpenPR&utm_medium=10144

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

This release was published on openPR.